clinical trial · NCT06202261
A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·phase2·recruiting·n = 154
Metastatic Breast CancerRecurrent Breast CancerAdvanced MalignanciesTQB2930 for injectionPaclitaxel for injection (albumin-bound)TQB3616 capsuleFulvestrant injectionCapecitabine tabletsVinorelbine tartrate injectionEribulin mesylate injectiongemcitabine hydrochloride for injection
brief summary
This is a phase Ib/II exploratory study. Phase Ib includes the dose escalation and expansion study of monotherapy, as well as the dose escalation study of combination therapy. After determining the maximum tolerated dose (MTD), a dose expansion study is conducted to observe the safety and efficacy in monotherapy. Phase II study is to further observe the safety and efficacy of TQB2930 combined with albumin-paclitaxel (cohort 3), or chemotherapy selected by investigators (cohort 4).
started
Apr 13, 2023
primary completion
Dec 1, 2026
completion
Oct 1, 2027
last updated
Mar 12, 2024
official title
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of TQB2930 for Injection Monotherapy or in Combination for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Recurrent / Metastatic Breast Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol